Improvement of diabetic macular edema after micropulse laser therapy
Purpose MicroPulse technology (MP) is a new technique using a subthreshold laser micropulse. The desired effect is to reduce the laser damage to ocular tissue; its application in the macular area is very promising in order to treat diabetic macular edema (DME) with the less retinal damage. We presen...
Uložené v:
| Vydané v: | Acta ophthalmologica (Oxford, England) Ročník 94; číslo S256 |
|---|---|
| Hlavní autori: | , , , , , |
| Médium: | Journal Article |
| Jazyk: | English |
| Vydavateľské údaje: |
Malden
Wiley Subscription Services, Inc
01.10.2016
|
| Predmet: | |
| ISSN: | 1755-375X, 1755-3768 |
| On-line prístup: | Získať plný text |
| Tagy: |
Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
|
| Abstract | Purpose
MicroPulse technology (MP) is a new technique using a subthreshold laser micropulse. The desired effect is to reduce the laser damage to ocular tissue; its application in the macular area is very promising in order to treat diabetic macular edema (DME) with the less retinal damage.
We present our 6 months experience with MicroPulse Laser Therapy in DME using a new multifunctional laser, the IRIDEX IQ577.
Methods
We used MP as first‐line therapy in cases of diffuse DME if central macular thickness (CMT) was <300 μm. However, if DME was diffuse and CMT was >400 μm, we began anti‐VEGF therapy to reduce CMT and improve vision as quickly as possible. We began with the laser set in traditional settings. We placed a test spot in a non‐edematous area of the retina and we increased the power up moving to a new area each time, until we note a thermal reaction (white burn). In the second step, we switch the laser to the micropulse setting and perform MP over the area of edema with a high‐density grid treatment.
Results
Ten eyes of 8 patients were included. Mean age at diagnosis was 63.5 years. Best‐corrected visual acuity was 0.88 logmar (range 1.7–0.3) before treatment. After three months of MP, it improved to 0.67 logmar (range 1.4–0.2), p: 0.002. CMT was 367 μm, and improved to 316.5 μm (p: 0.14) at 1 month after treatment and to 291.2 μm at 3 months (p: 0.04). OCT detected early retinal reflectivity changes after treatment. All patients reported subjective improvement. No adverse events were observed during follow‐up.
Conclusions
MP laser is an effective laser to treat DME. Moreover, the attractive safety profile of MP treatment allows clinicians to offer earlier treatment to prevent tissue damage and the development of visual disability. |
|---|---|
| AbstractList | Purpose MicroPulse technology (MP) is a new technique using a subthreshold laser micropulse. The desired effect is to reduce the laser damage to ocular tissue; its application in the macular area is very promising in order to treat diabetic macular edema (DME) with the less retinal damage. We present our 6 months experience with MicroPulse Laser Therapy in DME using a new multifunctional laser, the IRIDEX IQ577. Methods We used MP as first-line therapy in cases of diffuse DME if central macular thickness (CMT) was <300 µm. However, if DME was diffuse and CMT was >400 µm, we began anti-VEGF therapy to reduce CMT and improve vision as quickly as possible. We began with the laser set in traditional settings. We placed a test spot in a non-edematous area of the retina and we increased the power up moving to a new area each time, until we note a thermal reaction (white burn). In the second step, we switch the laser to the micropulse setting and perform MP over the area of edema with a high-density grid treatment. Results Ten eyes of 8 patients were included. Mean age at diagnosis was 63.5 years. Best-corrected visual acuity was 0.88 logmar (range 1.7-0.3) before treatment. After three months of MP, it improved to 0.67 logmar (range 1.4-0.2), p: 0.002. CMT was 367 µm, and improved to 316.5 µm (p: 0.14) at 1 month after treatment and to 291.2 µm at 3 months (p: 0.04). OCT detected early retinal reflectivity changes after treatment. All patients reported subjective improvement. No adverse events were observed during follow-up. Conclusions MP laser is an effective laser to treat DME. Moreover, the attractive safety profile of MP treatment allows clinicians to offer earlier treatment to prevent tissue damage and the development of visual disability. Abstract only Purpose MicroPulse technology (MP) is a new technique using a subthreshold laser micropulse. The desired effect is to reduce the laser damage to ocular tissue; its application in the macular area is very promising in order to treat diabetic macular edema (DME) with the less retinal damage. We present our 6 months experience with MicroPulse Laser Therapy in DME using a new multifunctional laser, the IRIDEX IQ577. Methods We used MP as first‐line therapy in cases of diffuse DME if central macular thickness (CMT) was <300 μm. However, if DME was diffuse and CMT was >400 μm, we began anti‐VEGF therapy to reduce CMT and improve vision as quickly as possible. We began with the laser set in traditional settings. We placed a test spot in a non‐edematous area of the retina and we increased the power up moving to a new area each time, until we note a thermal reaction (white burn). In the second step, we switch the laser to the micropulse setting and perform MP over the area of edema with a high‐density grid treatment. Results Ten eyes of 8 patients were included. Mean age at diagnosis was 63.5 years. Best‐corrected visual acuity was 0.88 logmar (range 1.7–0.3) before treatment. After three months of MP, it improved to 0.67 logmar (range 1.4–0.2), p: 0.002. CMT was 367 μm, and improved to 316.5 μm (p: 0.14) at 1 month after treatment and to 291.2 μm at 3 months (p: 0.04). OCT detected early retinal reflectivity changes after treatment. All patients reported subjective improvement. No adverse events were observed during follow‐up. Conclusions MP laser is an effective laser to treat DME. Moreover, the attractive safety profile of MP treatment allows clinicians to offer earlier treatment to prevent tissue damage and the development of visual disability. |
| Author | Kortli, M. Chebil, A. El Matri, K. El Matri, L. Falfoul, Y. Chebbi, Z. |
| Author_xml | – sequence: 1 givenname: L. surname: El Matri fullname: El Matri, L. – sequence: 2 givenname: Y. surname: Falfoul fullname: Falfoul, Y. – sequence: 3 givenname: Z. surname: Chebbi fullname: Chebbi, Z. – sequence: 4 givenname: M. surname: Kortli fullname: Kortli, M. – sequence: 5 givenname: K. surname: El Matri fullname: El Matri, K. – sequence: 6 givenname: A. surname: Chebil fullname: Chebil, A. |
| BookMark | eNqNkEtLxDAUhYOM4MzoTxAKrluTpnnU3TA-YWAWKrgLmeQGW_oybZX596aOzFLM5obDOffxLdCsaRtA6JLghIR3XSZEMBZTwWWSYsITzCg7QfOjOjv-2dsZWvR9iTEnnGdzdPtUd779hBqaIWpdZAu9g6EwUa3NWGkfgYVaR9oN4KO6ML7txqqHqNJ9EIZ38Lrbn6NTp4N68VuX6PX-7mX9GG-2D0_r1SY2JGwUc5MK64iUzPIUuM6EkCmhjuxywV0uLbVWEswsprkAY7gDZ3KXc8DWZDKlS3R16BtW_hihH1TZjr4JIxXJQ1-cSYb_dEmSY05FJoKLHVzhpL734FTni1r7vSJYTVhVqSZoagKoJqxqwhpyN4fcV1HB_n8htdo-_4S_AVhGfPU |
| ContentType | Journal Article |
| Copyright | Copyright © 2016 Acta Ophthalmologica Scandinavica Foundation |
| Copyright_xml | – notice: Copyright © 2016 Acta Ophthalmologica Scandinavica Foundation |
| DBID | AAYXX CITATION 7TK |
| DOI | 10.1111/j.1755-3768.2016.0535 |
| DatabaseName | CrossRef Neurosciences Abstracts |
| DatabaseTitle | CrossRef Neurosciences Abstracts |
| DatabaseTitleList | Neurosciences Abstracts CrossRef Neurosciences Abstracts |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1755-3768 |
| EndPage | n/a |
| ExternalDocumentID | 4180593741 10_1111_j_1755_3768_2016_0535 AOS0535 |
| Genre | abstract |
| GroupedDBID | --- .3N .55 .GA .Y3 05W 0R~ 10A 1OC 23M 24P 31~ 33P 36B 3SF 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5HH 5LA 5VS 66C 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHHS AAHQN AAIPD AAMNL AANLZ AAONW AASGY AAXRX AAYCA AAZKR ABCUV ABDBF ABEML ABJNI ABPVW ABQWH ABXGK ACAHQ ACCFJ ACCZN ACGFS ACGOF ACMXC ACNCT ACPOU ACPRK ACSCC ACUHS ACXBN ACXQS ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZMN ADZOD AEEZP AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFFPM AFGKR AFPWT AFRAH AFWVQ AFZJQ AHBTC AHMBA AIACR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB ASPBG ATUGU AVWKF AZBYB AZFZN AZVAB BAFTC BAWUL BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 CAG COF CS3 D-6 D-7 D-E D-F DCZOG DIK DPXWK DR2 DRFUL DRMAN DRSTM E3Z EAD EAP EBC EBD EBS EJD EMB EMK EMOBN ESX EX3 F00 F01 F04 F5P FIJ FUBAC G-S GODZA H.X HF~ HGLYW HZI HZ~ IPNFZ IX1 J0M K48 KBYEO LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ O66 O9- OIG OK1 OVD P2W P2X P2Z P4B P4D P6G PQQKQ Q.N Q11 QB0 R.K RIWAO RJQFR ROL RX1 SUPJJ SV3 TEORI TR2 TUS UB1 V9Y W8V W99 WBKPD WHWMO WIH WIJ WIK WIN WOHZO WOW WQJ WRC WVDHM WXI WXSBR X7M XG1 ~IA ~WT AAMMB AAYXX AEFGJ AEYWJ AGHNM AGXDD AGYGG AIDQK AIDYY CITATION O8X 7TK |
| ID | FETCH-LOGICAL-c1535-6c27df1885d62e6a4778213f1b976f98d3dd8105d0397ecc6fefc9f96e0dc4823 |
| IEDL.DBID | DRFUL |
| ISSN | 1755-375X |
| IngestDate | Sat Nov 29 14:56:42 EST 2025 Sat Nov 29 14:56:58 EST 2025 Sat Nov 29 01:34:42 EST 2025 Wed Jan 22 16:17:44 EST 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | S256 |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c1535-6c27df1885d62e6a4778213f1b976f98d3dd8105d0397ecc6fefc9f96e0dc4823 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 |
| PQID | 1819063747 |
| PQPubID | 1036384 |
| PageCount | 1 |
| ParticipantIDs | proquest_journals_1918804850 proquest_journals_1819063747 crossref_primary_10_1111_j_1755_3768_2016_0535 wiley_primary_10_1111_j_1755_3768_2016_0535_AOS0535 |
| PublicationCentury | 2000 |
| PublicationDate | October 2016 2016-10-00 20161001 |
| PublicationDateYYYYMMDD | 2016-10-01 |
| PublicationDate_xml | – month: 10 year: 2016 text: October 2016 |
| PublicationDecade | 2010 |
| PublicationPlace | Malden |
| PublicationPlace_xml | – name: Malden |
| PublicationTitle | Acta ophthalmologica (Oxford, England) |
| PublicationYear | 2016 |
| Publisher | Wiley Subscription Services, Inc |
| Publisher_xml | – name: Wiley Subscription Services, Inc |
| SSID | ssj0061664 |
| Score | 2.1192057 |
| Snippet | Purpose
MicroPulse technology (MP) is a new technique using a subthreshold laser micropulse. The desired effect is to reduce the laser damage to ocular tissue;... Abstract only Purpose MicroPulse technology (MP) is a new technique using a subthreshold laser micropulse. The desired effect is to reduce the laser damage to ocular tissue;... |
| SourceID | proquest crossref wiley |
| SourceType | Aggregation Database Index Database Publisher |
| SubjectTerms | Acuity Diabetes Diabetes mellitus Edema Lasers Ophthalmology Retina Vascular endothelial growth factor |
| Title | Improvement of diabetic macular edema after micropulse laser therapy |
| URI | https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fj.1755-3768.2016.0535 https://www.proquest.com/docview/1819063747 https://www.proquest.com/docview/1918804850 |
| Volume | 94 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVWIB databaseName: Wiley Online Library Free Content customDbUrl: eissn: 1755-3768 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0061664 issn: 1755-375X databaseCode: WIN dateStart: 20080101 isFulltext: true titleUrlDefault: https://onlinelibrary.wiley.com providerName: Wiley-Blackwell – providerCode: PRVWIB databaseName: Wiley Online Library Full Collection 2020 customDbUrl: eissn: 1755-3768 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0061664 issn: 1755-375X databaseCode: DRFUL dateStart: 20080101 isFulltext: true titleUrlDefault: https://onlinelibrary.wiley.com providerName: Wiley-Blackwell |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3LS8MwGP-Ym4gX3-J0jhy8drRNk6bH4ZwKOkUd7hbaPGCHbbJOwf_eJG11Qw8ingopScv3yi9fvgfAWeTrRMUx9nBorxm10B6jkfKophHJdJhFkrlmE_FgwEaj5L4Gl1UuTFEf4tPhZjXD2Wur4GmWryp5TIhVEBehRTu2UskaNEIjw6QOjd5Df3hTGWUaUFdJqpxCRmUyTxXU822h1W3qC3suI1i3BfW3_-3nd2CrRKGoW4jNLtTUdA82bst79n3oFb4G5zpEM40KD-1YoEnq4laRkmqSItdgHE3GRRuwXCEDxc1AkdP1fgDD_sXT-ZVX9lvwhLF7xKMijKUOGCOShoqmUWzgQ4B1kBnMohMmsZTM4DHpGxBjWE-10iLRCVW-FBEL8SHUp7OpOgJkUDARQYwFNYBMMZpl5uSkzSIhjRXRtAmdirz8pSirwZeOI4Y23NKGW9pwS5smtCom8FLLch5YOEOxORH9_DqxxeYiRvwmYMeN332Ld-8e7fP4T7NOYNOOFQF_Lagv5q_qFNbF22Kcz9ulXLZh7fl68AEhO9_D |
| linkProvider | Wiley-Blackwell |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LTwIxEJ4gGvXi24ii9uB1yb762CNRCURYTcTIrWH7SDgABtDEf2_b3VWIHozxtMk27W5mOtNvpvMAuIp9nShKIy8K7TWjFtpjJFYe0STGmQ6zWDLXbIKmKRsMkocKtMtcmLw-xKfDzUqG09dWwK1DelXKKcZWQlyIFmnYUiVrsB4b0GGbODx30lInk4C4QlLFBDwocnnKmJ5vy6yeUl_QcxnAuhOotft__74HOwUKRc182-xDRU0OYLNX3LMfwk3ua3CuQzTVKPfQjgQaD13cKlJSjYfINRhH41HeBmyukIHi5kWe0_V-BE-t2_512yv6LXjC6D3sERFSqQPGsCShIsOYGvgQRDrIDGbRCZORlMzgMekbEGNYT7TSItEJUb4UMQujY6hOphN1AsigYCwCGgliAJliJMuM5aTNIiGhCmtSg0ZJX_6Sl9XgS-aIoQ23tOGWNtzSpgb1kgu8kLI5DyycIZGxiH4eTmyxuZhhvwaRY8fvvsWb94_2efqnWZew1e73urzbSe_OYNuO58F_daguZq_qHDbE22I0n124LfoBrx_hdg |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Improvement+of+diabetic+macular+edema+after+micropulse+laser+therapy&rft.jtitle=Acta+ophthalmologica+%28Oxford%2C+England%29&rft.au=El+Matri%2C+L&rft.au=Falfoul%2C+Y&rft.au=Chebbi%2C+Z&rft.au=Kortli%2C+M&rft.date=2016-10-01&rft.pub=Wiley+Subscription+Services%2C+Inc&rft.issn=1755-375X&rft.eissn=1755-3768&rft.volume=94&rft.issue=S256&rft_id=info:doi/10.1111%2Fj.1755-3768.2016.0535&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1755-375X&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1755-375X&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1755-375X&client=summon |